Media & press kit

Bloodstream infections and sepsis kill one in five worldwide. Cambridge Nucleomics is a diagnostics start-up developing a rapid, low-input technology platform for highly multiplexed RNA and DNA biomarker detection. Spun out of the University of Cambridge and based at the Babraham Research Campus, the company's proprietary enzyme-free nanoarray technology labels and counts nucleic acid biomarkers with single-molecule accuracy and will deliver actionable results in under one hour in a clinical setting. Cambridge Nucleomics is currently advancing its lead programme in rapid pathogen identification and genetic antimicrobial resistance (AMR) testing directly from blood without culture, while exploring a pipeline of applications in oncology diagnostics.